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TObjectives: We sought to review the incidence and outcome of lung transplantation
complications observed over 15 years at a single center.
Methods: We performed a retrospective review from our databases, tracking outcomes
after adult and pediatric lung transplantation. The 983 operations between July 1988 and
September 2003 included 277 pediatric and 706 adult recipients. Bilateral (74%),
unilateral (19%), and living lobar transplants (4%) comprised the bulk of this experi-
ence. Retransplantations accounted for 44 (4.5%) of the operations.
Results: The groups differed by indication for transplantation. The adults in-
cluded 57% with emphysema and 17% with cystic fibrosis, and the children
included no patients with emphysema and 50% with cystic fibrosis. Hospital
mortality was 96 (9.8%) of 983, including 46 (17%) of 277 of the children and
50 (7%) of 706 of the adults. The overall survival curves did not differ between
adults and children (P  .56). Freedom from bronchiolitis obliterans syndrome
at 5 and 10 years was 45% and 18% for adults and 48% and 30% for children,
respectively (P  .53). The causes of death for adults included bronchiolitis
obliterans syndrome (40%), respiratory failure (17%), and infection (14%),
whereas the causes of death in children included bronchiolitis obliterans syn-
drome (35%), infection (28%), and respiratory failure (21%) (P  .01). Post-
transplantation lymphoproliferative disease occurred in 12% of pediatric recip-
ients and 6% of adults (P  .01). The frequency of treated airway complications
did not differ between adults and children (9% vs 11%, P  .48). The frequency
of primary graft dysfunction did not differ between children (22%) and adults
(23%), despite disparity in the use of cardiopulmonary bypass.
Conclusion: These results highlight major complications after lung transplantation.
Despite differences in underlying diagnoses and operative techniques, the 2 cohorts
of patients experienced remarkably similar outcomes.
Lung transplantation has been transformed from extraordinary therapy in theearly 1980s to widely available therapy in the current era. The transformationhas been marked by a change in recipient selection, from those who were
facing certain death with no options in the early 1980s to patients looking to increase
both life expectancy and functional status in the current era. Attitudes concerning
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well, from the initial amazement that it could be done
successfully at all to increasing pressure to reduce morbidity
and mortality while at the same time justifying the expense
with cost-effectiveness analyses. Both the effectiveness and the
cost of lung transplantation are greatly affected by complica-
tions. We chose to review important selected complications
of our overall lung transplantation program from the time of
its inception to highlight important differences between the
adult and pediatric programs and to identify trends in the
incidence and severity of our complications over time. The
goal is to provide increased awareness of such trends and to
discuss how they might affect future work in the field of
lung transplantation.
Methods
This report is a single-center retrospective report that examines
complications after lung transplantation in adults and children.
The lung transplantation program at Washington University is
composed of 2 independent programs. The adult lung transplan-
tation effort opened in 1988, and the pediatric program began in
1990. Since the start of the program at Children’s Hospital, the
TABLE 1. Recipients stratified by pediatric versus adult cl
Pediatric (n 
Age (y) 10.7 6.4; 12.1 (IQ
Sex (F) 156 (56.3%
Diagnosis
Emphysema 0 (0%)
Cystic fibrosis 138 (49.8%
Pulmonary vascular disease 71 (25.6%
Other pulmonary disease 68 (24.6%
Time on the waiting list (d) 176 (IQR,
Type of transplantation performed
Bilateral 204 (73.6%
Single 8 (2.9%
Heart-lung 16 (5.8%
Bilateral lobar (living) 39 (14.1%
Bilateral lobar (cadaveric) 4 (1.4%
Single lobe 1 (0.4%
Bilateral-liver 5 (1.8%
Length of mechanical ventilation (d) 5 (IQR,
Length of stay in ICU (d) 7 (IQR,
Length of stay in hospital (d) 19 (IQR,
Required ECMO support after
transplantation
27 (9.7%
Primary graft dysfunction* 62 (22.4%
Hospital mortality 46 (16.6%
Treated for airway complication 30 (10.8%
Diagnosed with posttransplantation
lymphoproliferative disease
32 (11.6%
IQR, Interquartile range; ICU, intensive care unit; ECMO, extracorporeal m
inspired oxygen of 150 or less on initial or 24-hour arterial blood gas; Peds:
chest radiograph consistent with reperfusion injury, biopsy.2 programs have been managed separately, with distinct sur-
1422 The Journal of Thoracic and Cardiovascular Surgery ● Jungeons and pulmonologists at each institution. There has been
close interchange of results and sharing of innovation. The
databases of the 2 programs were used jointly in this project to
provide a single-center look at lung transplantation since the
onset of the 2 programs. The databases for the 2 programs were
queried to obtain data regarding the indications for and out-
comes of all lung transplantations performed since 1988 at St
Louis Children’s Hospital and Barnes-Jewish Hospital. Individ-
ual patient records were consulted only to verify missing,
incomplete, or suspect data.
Patient Population
The patients in this report include all patients undergoing lung trans-
plantation or heart-lung transplantation at Barnes-Jewish Hospital or
St Louis Children’s Hospital from July 1988 through September
2003. Table 1 describes the demographic data of these patients.
Surgical Technique
The techniques have been well described elsewhere.1,2 In general, the
techniques have been consistent over time and between the 2 pro-
grams, with a few notable exceptions. Although both programs prefer
the bilateral lung transplantation option, the pediatric group has per-
formed some form of bilateral transplantation in 268 (97%) of 277
fication
Adult (n  706) P value
4-15.8) 47.6 12.2; 50.5 (IQR, 38.9-57.6)
357 (50.6%) .118
.001
399 (56.5%)
118 (16.7%)
63 (8.9%)
126 (17.8%)
5) 488 (IQR,281-665) .001
.001
526 (74.5%)
176 (24.9%)
4 (0.6%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
2 (IQR, 1-4) .001
3 (IQR, 2-5) .001
) 17 (IQR, 12-24) .001
20 (2.8%) .001
160 (22.7%) 1.000
50 (7.1%) .001
66 (9.3%) .476
42 (5.9%) .004
rane oxygenation. *Adults: arterial partial pressure of oxygen/fraction of
anical ventilation 7 days, retransplantation 7 days of initial transplant,assi
277)
R, 5.
)
)
)
)
42-46
)
)
)
)
)
)
)
2-14)
4-17)
13-33
)
)
)
)
)
emb
mechoperations, whereas the adult experience includes bilateral transplan-
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operations were performed with cardiopulmonary bypass because of
the relative difficulties of double-lumen endotracheal tube use in
children and the prevalence of pulmonary hypertension in the pedi-
atric cohort. On the other hand, the rate of bypass support in the adult
population varied greatly according to diagnosis and the presence of
pulmonary hypertension.
Postoperative Management
Routine postoperative management has been discussed else-
where.3,4 In general, the management has been consistent over
time and between the 2 programs. Both programs have depended
on 3-drug immunosuppression (typically prednisone, cyclosporine
[INN: ciclosporin], and azathioprine), and both programs have
routine scheduled surveillance bronchoscopy to guide the mainte-
nance immunosuppression.
Statistical Analysis
Descriptive statistics were expressed as means  standard devia-
tion unless otherwise specified. Categoric data were expressed as
counts and proportions. Comparisons were done with paired,
2-tailed t tests for means of normally distributed continuous vari-
ables and Wilcoxon rank sum tests for skewed data. Fisher exact
or 2 tests were used to analyze differences among the categorical
data. Kaplan-Meier estimate was used to depict survival. All data
analysis was performed with SPSS software (SPSS 11.0 for Win-
dows; SPSS Inc, Chicago, Ill).
Results
During the period of reporting, there were 983 lung trans-
plantations, including 277 performed at St Louis Children’s
Hospital and 706 at Barnes-Jewish Hospital. Although these
might roughly be partitioned as pediatric and adult trans-
plantations, there was some small overlap with regard to age
(Figure E1). Overall hospital mortality was 96 (9.8%) of
983 and included 46 (17%) of 277 in the pediatric group and
50 (7%) of 706 in the adult group. The typical waiting time
for donor lungs varied according to transplantation site.
There was a statistically significant difference in the distri-
bution of recipient diagnoses, with the notable predomi-
nance of cystic fibrosis as a leading diagnosis for the chil-
dren and emphysema as the most common indication for
transplantation in the adults. In both locations the split
according to sex was approximately equal. There were
statistically significant and clinically meaningful differences
in the duration of mechanical ventilation and duration of
intensive care unit (ICU) stay after lung transplantation. The
children remained intubated for a median of 5 days (inter-
quartile range, 2-14), whereas the adults experienced a
median length of mechanical ventilation of 2 days (inter-
quartile range, 1-4 days).
Primary Graft Dysfunction
One of the most important complications of lung trans-
plantation is primary graft dysfunction (PGD). This term
The Journal of Thoracicincludes a wide variety of other definitions, including
ischemia-reperfusion injury, implantation response, acute
lung injury, and hyperacute rejection. Although the cod-
ing of the databases at St Louis Children’s Hospital and
Barnes-Jewish Hospital have slightly different criteria for
coding a case as “yes” for PGD, the incidence has been
consistent throughout the experience and is comparable
with that seen in multiple reports from other programs in
the literature. At Barnes-Jewish Hospital, the criteria for
PGD are based on the ratio of PaO2 divided by the
fraction of inspired oxygen in the first 48 hours after
transplantation. Cases were defined as those having a
PaO2/fraction of inspired oxygen ratio of less than 150
mm Hg in the first 48 hours. At Children’s Hospital, the
coding was performed by one of the authors (S.C.S.),
who identified cases as those demonstrating the presence
of (1) mechanical ventilation beyond 7 days after trans-
plantation or experiencing retransplantation before 7
days and (2) either chest radiographs showing panlobar
alveolar infiltrates or lung biopsy diagnosis of diffuse
alveolar damage or reperfusion injury. We identified 62
(22.4%) of 277 pediatric cases and 160 (22.7%) of 706
adult cases of PGD in this manner. The incidence of PGD
varied slightly over time, but the differences were not
larger than one might expect from chance alone (Table
2). There was a statistically significant difference in the
distribution of PGD according to the underlying diagno-
sis leading to transplantation. There was an apparent
excess of PGD in the patients who underwent transplan-
tation for pulmonary hypertension and an apparent spar-
ing of patients who underwent transplantation for
emphysema.
The effect of PGD on the transplantation program as a
whole is enormous. The mortality of patients with PGD
was 64 (28.8%) of 222 compared with 32 (4.2%) of 761
seen in those patients without the condition (P  .001).
The risk of death for the entire cohort of 983 patients that
is attributable to PGD can be estimated by the risk in the
total cohort (96/983 [9.8%]) minus the risk in the unex-
posed group (32/761 [4.2%]). Therefore the phenomenon
of PGD might be responsible for a mortality of 5.6% by
itself, more than half of the overall death rate for the
entire cohort (Figure 1).
In addition to the burden of excess mortality in patients
undergoing transplantation, PGD is also responsible for a
substantial increase in the cost of providing this medical
care. In these 980 patients, the costs that could be reason-
ably attributed to PGD can be estimated by multiplying the
increased resource use in the afflicted group by the number
of patients in that group. For instance, the 222 patients with
PGD were intubated for a median of 6 days, whereas those
without PGD were intubated for 2 days. The excess time of
intubation (4 days) associated with PGD can be multiplied
and Cardiovascular Surgery ● Volume 129, Number 6 1423
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on the ventilator attributable to the condition of PGD. A
similar difference in days in the ICU (7 for those with PGD
vs 3 for those without PGD) leads to an excess of 888
patient-days in the ICU attributable to PGD. The difference
in hospital stay for those with and without PGD is 7 days, and
therefore the attributable burden of hospital days is 7 times
222, or 1554, patient-days. Because 888 of the patient-days
are already counted in the ICU stay, this would amount to
1554 minus 888, or 666, non-ICU patient-days attributable
to PGD.
Another costly consequence of early lung dysfunction is
the burden of acute retransplantation. This controversial
therapy has been performed 11 times in our collective
experience, 5 in pediatric recipients and 6 in adults. In these
instances the resources consumed as a direct consequence of
PGD are not limited to financial and hospital resources.
TABLE 2. Factors associated with primary graft dysfunctio
PGD, no (n
Quintile of experience
7/1988-3/1993 144 (73.5%
4/1993-11/1995 154 (78.2%
12/1995-5/1998 156 (79.2%
5/1998-1/2001 161 (81.7%
1/2001-9/2003 146 (74.5%
Diagnosis
Emphysema 325 (81.5%
Cystic fibrosis 197 (77.0%
Pulmonary vascular disease 94 (70.1%
Other pulmonary disease 145 (74.7%
Ischemic time (min) 274
Length of mechanical ventilation (d) 2 (IQR, 1
Length of stay in ICU (d) 3 (IQR, 2
Length of stay in hospital (d) 16 (IQR, 1
Hospital mortality 32 (4.2%)
PGD, Primary graft dysfunction; IQR, interquartile range; ICU, intensive caFigure 1. Survival after lung transplantation stratified by PGD.
1424 The Journal of Thoracic and Cardiovascular Surgery ● JunThey also include the very limited availability of lung
allografts suitable for transplantation. In this manner the use
of acute retransplantation as a response to severe PGD has
survival implications even for patients on the waiting list
because their likelihood of undergoing successful transplan-
tation will decrease as the use of allografts for retransplan-
tation increases.
In addition to the acute effects of PGD, there has been
some evidence that this early difficulty increases the recip-
ient’s likelihood for chronic graft dysfunction as well. We
observed a small but statistically significant increase in the
hazard for chronic rejection in the survivors of PGD versus
those who did not have the condition. This tendency is
shown by the reduction in the mean time to development of
bronchiolitis obliterans syndrome (BOS), from 4.5 years
(95% confidence interval [CI], 3.8-5.2) in those without
PGD to 3.3 years (95% CI, 2.2-4.4) in those with PGD. A
comparison of freedom from BOS in those with and without
PGD revealed a statistically significant association by using
the log-rank test (P  .044, Figure E2).
One therapeutic intervention that might become neces-
sary in the acute management of early lung dysfunction is
extracorporeal membrane oxygenation (ECMO). We have
previously reported some outcomes of ECMO support in
our adult lung transplantation population and concluded that
the best likelihood for survival occurs when ECMO support
is instituted within 24 hours of the transplantation and lung
recovery allows weaning from ECMO within 48 hours of its
initiation.5 In this cumulative experience 47 of 983 patients
received ECMO support after the transplantation for the
constellation of findings consistent with PGD: poor oxygen-
ation despite maximal therapeutic interventions, stiff lungs
) PGD, yes (n  222) P value
.266
52 (26.5%)
43 (21.8%)
41 (20.8%)
36 (18.3%)
50 (25.5%)
.035
74 (18.5%)
59 (23.0%)
40 (29.9%)
49 (25.3%)
290  86 .003
6 (IQR, 2-18) .001
7 (IQR, 3-18) .001
) 23 (IQR, 13-39) .001
64 (28.8%) .001
it.n
 761
)
)
)
)
)
)
)
)
)
70
-4)
-6)
2-23with high airway pressures, and respiratory acidosis. There
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adult recipient and the use of ECMO, with 27 (9.7%) of 277
pediatric patients requiring ECMO, whereas 20 (2.8%) of
706 adult patients were started on ECMO postoperatively.
The mortality among the ECMO recipients was 29 (62%) of
47, with a relative risk of death of 8.6 (95% CI, 6.3-11.9)
compared with the non-ECMO recipients.
Airway Anastomotic Complications
One of the sentinel complications in lung transplantation is
the development of an airway anastomotic complication that
requires therapy.6 In our overall cohort there was no asso-
ciation between the rate of airway complications and clas-
sification of adult versus pediatric transplantation. The
adults experienced a rate of anastomotic complication of 66
(9.3%) of 706, whereas the pediatric airway complication
rate was 30 (10.8%) of 277. In review of the entire experi-
ence over time, there was an association between the rate
and quintile of experience (P  .016), with the highest rate
occurring in the initial quintile of experience from 1988
through 1993 (Table 3). There was no association between
patient diagnosis and the rate of anastomotic complications
(P  .72). Analysis to determine the effect of acute graft
dysfunction on the development of airway complications
failed to show a statistically significant association between
these outcomes. The odds ratio describing the association
between PGD and subsequent airway complications is 1.2
(95% CI, 0.8-1.85).
Although airway complications appear to affect about
10% of our transplant recipients and might lead to in-
creased costs and decreased quality of life, the presence
of an airway complication does not appear to be associ-
TABLE 3. Factors associated with airway anastomotic com
AC, no (n  8
Population
Adult 640 (90.7%)
Pediatric 247 (89.2%)
Quintile
7/1988-3/1993 165 (84.2%)
4/1993-11/1995 178 (90.4%)
12/1995-5/1998 185 (93.9%)
5/1998-1/2001 182 (92.4%)
1/2001-9/2003 177 (90.3%)
Diagnosis
Emphysema 364 (91.2%)
Cystic fibrosis 232 (90.6%)
Pulmonary vascular disease 119 (88.8%)
Other pulmonary disease 172 (88.7%)
Primary graft dysfunction 197 (22.2%)
Hospital mortality 86 (9.7%)
AC, Anastomotic complications.ated with survival. The hospital mortality of those with
The Journal of Thoracican airway complication was 10 (10%) of 96 versus a
mortality for those without airway complications of 86
(9.7%) of 887. The log-rank test comparing overall sur-
vival in the 2 groups showed no association between
airway complication and survival (P  .76). The median
survival of those with an airway complication was 6.9
years (95% CI, 4.1-9.6), whereas the median survival of
those without airway complications was 6.1 years (95%
CI, 2.8-6.2). This comparison might be biased by the fact
that very early mortality would prevent a patient from
being alive long enough to be at risk for a symptomatic
and treatable airway complication.
BOS and Posttransplantation Lymphoproliferative
Disease
Although PGD is the dominant problem faced early after
lung transplantation, the development of chronic rejection
or BOS is the major driver of morbidity in the late post-
transplantation period. Figure E3 shows that there is no
difference between the adult and the pediatric experience
with regard to freedom from BOS over time. The median
time to the diagnosis of BOS is 4.5 years (95% CI, 2.8-6.2)
for the pediatric group and 4.3 years (95% CI, 3.6-4.9) for
the adult population.
The frequency with which posttransplantation lympho-
proliferative disease (PTLD) was diagnosed in the post-
transplantation period is 5.9% of the adults and 11.6% of the
children (P  .004). We do not have full data on pretrans-
plantation Epstein-Barr virus status and cannot provide fur-
ther analysis with regard to risk factors for the development
of this serious complication.
Long-term survival is also comparable between the
ations
AC, yes (n  96) P value
.476
66 (9.3%)
30 (10.8%)
.016
31 (15.8%)
19 (9.6%)
12 (6.1%)
15 (7.6%)
19 (9.7%)
.718
35 (8.8%)
24 (9.4%)
15 (11.2%)
22 (11.3%)
25 (26.0%) .440
10 (10.4%) .856plic
87)groups. The 10-year survival curves are depicted in Fig-
and Cardiovascular Surgery ● Volume 129, Number 6 1425
Cardiothoracic Transplantation Meyers et al
TXure 2. There is no significant difference between the
survival curves (P  .56), and the median time to death
is 5.9 years (95% CI, 4.4-7.4) for the pediatric cohort and
6.3 years (95% CI, 5.6-7.0) for the adults. The causes of
death are listed in Figure 3, with BOS and graft failure
together accounting for the majority of the deaths.
Discussion
This article provides a single-center experience of the com-
plications of lung transplantation over a 15-year period. The
major limitation of such a report is the retrospective nature
of the work. The lung transplantation databases for the 2
hospitals described were not up and running at the time of
the first transplantation, and therefore many of the entries
were made after the fact at the time of the creation of the
databases. In some instances, the lack of a uniform defini-
tion might lead to differential reports of complications.
Another potential limitation of a cumulative report such as
this is the disparate nature of the 2 experiences. There are no
children who underwent transplantation for emphysema, yet
that diagnosis makes up the largest fraction of the adult
cohort. On the other hand, secondary pulmonary hyperten-
sion caused by a congenital heart disorder is an extremely
unusual indication for an adult but a common one for an
infant. To analyze all of these patients together is an invi-
tation to introduce bias and confounding.
Lung transplantation is a therapy for which the costs and
incremental cost-effectiveness ratio are coming under in-
creasing scrutiny. Many analyses have concluded that it is
an expensive but effective therapy. A study by the Univer-
sity of Pittsburgh in 1997 reported median costs of $94,000
per transplantation and average costs of $154,000 per trans-
plantation, a disparity that was due to some higher cost
outliers.7 A Dutch study in 1998 that assessed incremental
Figure 2. Survival after ling transplantation stratified by patient
population.cost-effectiveness of transplantation over medical therapy
1426 The Journal of Thoracic and Cardiovascular Surgery ● Junreported a baseline scenario in which the incremental cost
per quality-adjusted life year gained was $116,000 for lung
transplantation compared with medical therapy.8 The most
recent and comprehensive of such analyses was the UK
study that compared the cost-effectiveness of single, bilat-
eral, and heart-lung transplantation with an estimated cost
per quality-adjusted life year for these operations of
$48,000, $33,000, and $29,000, respectively. Although the
latter estimates are within the range of values that society is
Figure 3. Cause of death stratified by adult versus pediatric
status. CNS, Central nervous system; BO, bronchiolitis obliterans.readily willing to pay for health care interventions, the other
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situation in the United States.9
It is apparent from these data that PGD creates a sub-
stantial burden on the population of lung transplant recipi-
ents. On the basis of the attributable risks of death, hospital
resource consumption, and allograft, a reduction of the rate
of PGD by 50% (from 22% to 11%) in our population could
have saved 50 lives, eliminated the need for 6 retransplan-
tations, and reduced hospital resource consumption by more
than 400 ICU-ventilator days, as well as more than 300
additional non-ICU days. Our review did not reveal any
reliable clinical prediction rules that might identify high-
risk recipients or donors, and our rate of PGD appears
comparable with rates reported by others.10-13
The differences we report in the rates of PTLD in chil-
dren and adults confirms earlier work by others who have
reported rates of 5% or less in adults and rates as high as
16% in children.14-17 Risk factors for this neoplasm appear
to be pretransplant seronegativity for Epstein-Barr virus and
lower age. It is typical for reports to describe a 50% mor-
tality, with the majority of the deaths occurring within a few
months of the diagnosis of the PTLD.17-20
It is a bit concerning that the trend of any specific
complication over time does not show a steady trend toward
elimination of that complication. The incidence of PGD
seemed to be trending downward, but a recent increase has
erased the improvements seen in the midportion of the
experience (Table 2). The rate of anastomotic complications
decreased rapidly in the early experience and has seen little
change in the last decade (Table 3). On the surface, one
might hope that experience would bring increased skill and
judgment sufficient to gradually eliminate all but the most
unpredictable complications. It is of course more compli-
cated than that. One must keep in mind the multiple subtle
changes in many aspects of these patients’ care that have
taken place over the period of observation. In the earliest
era, stringent criteria were required before declaring poten-
tial donor lungs acceptable for transplantation. Gradually,
experience accumulated that demonstrated the safety and
effectiveness of using less-than-perfect donor lungs for
most recipient indications. Other changes over the years
have been subtle evolution of anastomotic techniques, mul-
tiple alterations of lung procurement and cold preservation,
and intermittent changes to the cohort of surgeons perform-
ing the implantations. The growing list of waiting patients
makes transplantation teams now willing to accept organs
from distant cities with the full knowledge that the increased
travel times will prolong the ischemic times and increase the
risk for early and late graft dysfunction. In many instances
the changes in decision making have been a conscious
decision to accept the possibility of a less ideal outcome to
increase the supply of donor organs and therefore increase
the availability of lung transplantation in general.
The Journal of ThoracicConclusions
A focus on complications is important because it identifies
areas that can be prioritized for future work in reducing
costs and improving benefits of lung transplantation. If one
considers areas to improve the cost-effectiveness of a ther-
apy, the reduction of complications is a fertile area for
progress because those complicated patients have both the
highest cost of care and the worst quality and duration of
survival. The reduction might be achieved in many ways,
ranging from adjustments in technique to eliminate the
hazard of complications to adjustment in selection criteria to
emphasize potential recipients in whom a safe and effective
outcome is most likely to be achieved.
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Discussion
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Bryan, I con-
gratulate you and your colleagues at Washington University for
continuing to lead the field and set the benchmark in lung
transplantation. As you have noted, PGD is a particularly dev-
astating complication, and it has a great effect on the cost of this
treatment modality. Could you tell us what your definition for
PGD in the adult and pediatric population was for the purpose
of this study?
Dr Meyers. For the adults, we use the PaO2/fraction of inspired
oxygen ratio in the first 24 hours after transplantation, and the
patients who had a ratio of less than 150 were characterized as
having PGD. In the pediatric database, if they had radiographic
characteristics consistent with reperfusion injury and mechanical
ventilation for more than a week or acute retransplantation, they
were characterized as having PGD.
Dr Keshavjee. Second, the use of ECMO in children in your
experience was about 10%, whereas in adults it was 3%. Is this due
to an increased incidence of PGD, or is it perhaps a lower threshold
to institute this advanced therapy in a child rather than an adult?
Dr Meyers. Because this study lumps together disparate groups
of patients, it is challenging to answer such a question.
As you saw, on the basis of the criteria we used to characterize
the patients, the incidence of PGD was the same in adults and
children, yet either the severity or the response was different
between the pediatric surgeons and the adult surgeons. My sense is
that the severity in the children was worse because both groups of
surgeons are loathe to start an acute postoperative patient on
ECMO, and therefore the profound nature of the hypoxemia in the
children seemed to be worse and therefore merit ECMO more
frequently.
Dr Keshavjee. Finally, if we are going to encourage the use of
living donor transplantation, one of the reasons to do so might
theoretically be that you get a better quality graft from a non–
brain-dead donor or shorter ischemic time. Were there any advan-
tages with respect to complications or disadvantages that you
noted between your living donor experience and your deceased
donor experience?
Dr Meyers. Dr Blackstone would characterize that as an apples
and oranges comparison because the living donor recipients were
1428 The Journal of Thoracic and Cardiovascular Surgery ● Junonly the pediatric recipients, and they generally all had cystic
fibrosis. Our general philosophy has been to primarily use the
living donor strategy in patients who would not likely survive to
the time it would take to get a cadaveric donor. As a result, that
group is negatively biased by worse comorbidities. Therefore I do
not know whether such a comparison could be made.
Dr Larry R. Kaiser (Philadelphia, Pa). Bryan, I enjoyed the
article very much. I noticed in your most recent time period there
seemed to be a slight increase in the incidence of airway compli-
cations, as well as a slight increase in the incidence of PGD. Is this
because of your efforts to use these worst sort of donors or the
marginal sort of donors?
Dr Meyers. We touch on that in the article, and it is discon-
certing. You would like to see a gradual shaving away of compli-
cations as experience is accumulated, but there certainly have been
a lot of changes over the period of time in which these data were
accumulated. Use of more marginal donors and donors from longer
distance all might contribute to that uptick in the PGD rate and also
perhaps the anastomotic complication rate.
We are also liberal in terms of integrating the thoracic surgical
fellows and the transplantation fellows into the construction of the
anastomosis, and it might be that although the cumulative experi-
ence has been gained over 15 years, you reset the clock with each
new fellow every 6 months, and therefore there is a constant
relearning of what needs to be done.
Dr Malcolm M. DeCamp (Cleveland, Ohio). Bryan, congrat-
ulations, that is a fabulous series, and we look forward to you
mining these data for years to come to identify that low-hanging
fruit.
Over the course of your experience, have you changed any of
the procurement techniques, used different preservation solutions,
and/or modified your approach to using double-lung grafts, per-
haps for more marginal donors? Those things seem more likely to
affect PGD rather than some of the other things, such as the use of
induction immunosuppression or some of the longer-term deter-
minants of survival. The most dramatic thing that you have shown
is that all the factors that affect mortality occur acutely in the
hospitalization, whereas the long-term outcomes seem quite sim-
ilar. I wonder whether you could comment on what you have done
differently over the course of time and how those changes might
affect your reported outcomes.
Dr Meyers. As you can imagine, there have been a lot of
evolutionary changes. We did make a transition from a modifica-
tion of Euro-Collins to Perfadex a couple of years ago.
We have been very liberal for almost 10 years now using nitric
oxide in recipients. We have lately used some inhaled Flolan either
instead of or sometimes in addition to nitric oxide at the time of
implantation. And the interaction between the quality of the donor
and the recipient—there is certainly a real one there, but it is
difficult to capture in a talk like this.
Where you would be very reluctant to accept a marginal graft
for a single-lung transplant for pulmonary hypertension, you
would certainly consider it for a patient with emphysema, and a
patient with emphysema has very wide latitude with regard to the
size of bilateral lungs that you might put in, whereas other recip-
ients might be more constrained.
e 2005
Meyers et al Cardiothoracic TransplantationTherefore it is difficult to globalize over the experience, but
yes, there are a lot of small evolutionary changes that have taken
place.
Dr John Benfield (Los Angeles, Calif). I cannot help but recall
coming to Toronto when Joel Cooper had done his first successful
lung transplantation and the tribute that he paid at that time to Griff
Pearson and to the environment that permitted the development of
this field here in Toronto. Environment is so important, and even
though this might not add much to the science of what was
presented, at least it might add a touch of history.
Dr Thomas L. Spray (Philadelphia, Pa). I was quite struck by
the fact that the incidence of BOS was the same in the pediatric
and adult populations, and yet there have been several other studies
from your center suggesting that BOS is less common in the very
young patient.
In addition, because very young patients are hard to evaluate
for BOS, I wonder whether you could comment on how you madeThe Journal of Thoraciccompared that with the adult population because the diagnosis
might be quite difficult to make in a very young patient who cannot
do a pulmonary function test.
Dr Meyers. Thanks, Dr Spray, for that question. It is quite a
challenge. My recollection of the description from the St Louis
Children’s Hospital transplantation team about how they measure
pulmonary function tests in infants essentially amounts to a forced
exhalation measurement with a spirometer on a baby. The child is
basically squeezed around the chest and abdomen, and certainly
that is a very crude assessment of lung function.
But with regard to the reported freedom of BOS in the
youngest children, those children make up a very small fraction
of the overall pediatric experience, with a substantial fraction
being composed of teenagers who experienced a rate of BOS
similar to that observed in the adults. Therefore the classifica-
tion certainly is not ideal, but this is the best we can go on based
on the 2 databases that have been maintained throughout theTXthe diagnosis of BOS, especially in the pediatric population, and experience.and Cardiovascular Surgery ● Volume 129, Number 6 1429
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